全球首创“稻米造血”，科创成长层“第一股”今日申购丨打新早知道

Core Viewpoint - He Yuan Bio (688765.SH) is set to be listed on the Sci-Tech Innovation Board, focusing on plant-based recombinant protein expression technology and product development, with a leading global plant bioreactor technology platform [1][4]. Company Overview - He Yuan Bio is recognized as a pioneer in the "rice hematopoiesis" industry, developing multiple pharmaceutical products using a rice endosperm cell bioreactor expression system [1][4]. - The company has launched its core product, HY1001, a recombinant human albumin injection derived from rice, which received approval from the National Medical Products Administration in July 2023 [4][6]. Financial Performance - The company reported revenues of 13.40 million yuan in 2022, with a year-on-year decline of 47.49%, followed by an increase of 81.08% to 24.26 million yuan in 2023, and a slight increase of 3.92% to 25.22 million yuan projected for 2024 [5]. - The net profit attributable to the parent company showed losses of 143.58 million yuan in 2022, 186.96 million yuan in 2023, and a projected loss of 151.37 million yuan in 2024, with a year-on-year decline of 7.12%, 30.22%, and an increase of 19.04% respectively [5]. Market Position and Competition - He Yuan Bio is the first company to pass the registration process under the fifth set of standards for the Sci-Tech Innovation Board and is the first new issuance in the Sci-Tech Growth Layer [5]. - The company has established a sales network across over 30 provinces and cities in China, having signed distribution agreements with major pharmaceutical distributors [5][6]. - He Yuan Bio has eight drug candidates in its pipeline, with two in Phase II clinical trials and two in Phase I trials, alongside one drug approved for clinical trials [6]. Investment and Funding - The company plans to invest 19.09 billion yuan in the construction of a plant-based recombinant human serum albumin industrialization base, 7.94 billion yuan in new drug research and development, and 8.00 billion yuan to supplement working capital [3][5].